



ONE TO WATCH

L6, 121 King William St
Adelaide SA 5000
bakeryoung.com.au
ABN 92 006 690 320 AFSL 246735

INVEX THERAPEUTICS LIMITED (ASX:IXC)



In an enviable position, with ample working capital

Invex is in an enviable position, with ample working capital to see the company through the completion of phase 3 clinical trials, having achieved statistically significant results in both primary and secondary endpoints in phase 2 clinical trials. Subsequently, Invex raised A\$26m in May 2020 on the back of these results and will proceed as a sole entity until the completion of phase 3 clinical trials, thus strengthening their value proposition pending favorable results. The company currently has a A\$49m market cap (A\$17m Enterprise value), with A\$33m cash in the bank, whilst expensing A\$400,000 per quarter. This is something not seen often, hence our interest.

What does Invex do?

Invex is a biopharmaceutical company focused on the repurposing of approved drug, Exenatide, for efficacious treatment of neurological conditions derived from, or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke, and traumatic brain injury. In essence, uncontrolled production of fluid in the brain (cerebral spinal fluid), leads to excess pressure that manifests into compounding migraines, putting pressure and compressing the optic nerve around the eye causing deterioration in vision, and in some cases, permanent loss of vision. Invex has trademarked repurposed Exenatide as Presendin™.

Interestingly, 90% (10% men) women are sufferers, and predominantly of child bearing age with no known cause. IIH is confirmed as having Orphan Drug status, a disease or

disorder that affects fewer than 5 in 100,000 people (IIH 4.7 per 100,000). The symptoms of IIH are chronic and debilitating migraines, with 25% of sufferers experiencing a permanent loss of vision. Orphan drug legislation provides strong barriers disallowing any competitor the right to market an alternative treatment for seven and ten years, in the United States, and Europe respectively.

Currently there are no approved treatments for IIH, and no new drugs currently being tested in clinical trials, placing Invex in an attractive position to address a market with an unmet clinical need estimated to be worth US\$1.6 billion, growing at 3.4% annually (Europe & U.S ex rest of the world).

Invex recently employed Megan Baldwin, CEO of Opthea Limited as a Non Executive Director, to assist with Invex's aspirations. Megan's achievements, growing Opthea into a A\$500m market capitalisation company, illustrates a clear strategic benefit given her experience in ophthalmology.

Having achieved strong phase 2 clinical data, Invex has a defined regulatory pathway from the European Medicines Agency (EMA), providing guidance that a single successful phase 3 study will be satisfactory for commercial distribution. Currently Europe contributes 60% of the total addressable market, shared between the U.S and Europe. Invex has patents pending in both Japan and Europe, having been approved in the U.S.

As at April 2021 Invex filed, and received notification from the Food and Drug Administration (FDA), confirmation of a Type C meeting request where Invex will receive written responses to questions submitted by the company surrounding the proposed phase 3 trial design, and statistical analysis plan. Feedback is expected mid-June allowing Invex to ensure the FDA are satisfied with the phase 3 study approach before an Investigational New Drug application is submitted. It is unknown if the FDA will require multiple phase 3 trials, despite orphan status. Given IIH is a not a terminal condition, the FDA could request additional/ extended trials.

It is important to remember that Presendin™ is a repurposed molecule, currently sold as Exenatide in two formulations, Byetta and Bydureon for the treatment of type 2 diabetes by AstraZeneca, generating US\$300-400m per annum. Whilst

Disclaimer: Issued by Baker Young Limited ABN 92 006 690 320 - Australian Financial Services Licence 246735 and should be read in conjunction with the disclosure/disclaimer in this report.

patents are important, orphan drug status protects against AstraZeneca, (or anyone) competing over a 7-10 period (depending on jurisdiction).

Invex is yet to secure a long term product manufacturer to make the reformulation of Exenatide. This process is critical as the provider needs to be able to supply product for both clinical trials, and commercial production. Further, unit pricing and unit costs needs to be carefully balanced with the ability for customers to pay, coupled with a reimbursement scheme. The company states they are in advanced discussions with a handful of manufacturers.

In summary

As with all biopharmaceutical companies progressing through clinical trials, safety is paramount. As opposed to de novo drugs, Presendin™ (Exenatide) is a repurposed molecule which is administered subcutaneously (injection). Whilst Invex is required to perform minor tolerability and toxicology studies prior to IND application, neither is considered to be at risk of jeopardising the course of business, or the drug's safety profile, however not impossible. Progression of the above studies has been put on standby whilst the company works to lock in a long term supplier. Once confirmed, things begin to look interesting,

as the company can ramp up all aspects of the business. The second half of calendar year 2021 could see a strong pipeline of news flow based on the above coming to fruition. Given the current market capitalisation, and the company's relatively low daily turnover, it wouldn't take much for the share price to break its sideways run, and move aggressively to the upside. We acknowledge timing is crucial, where expectations can often be misplaced, or in Invex's case mispriced. That being said, we believe Invex is fundamentally undervalued. For the patient investor who understands the highly speculative and binary nature of biotechnology, we believe value exists around current levels.



- More** [Website](#)
- Watch** [March 2021 investor update](#)
- Read** [Invex Therapeutics Limited factsheet](#)

Important disclaimer: This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Baker Young Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the specified countries. • This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), the investment adviser who has provided you with this report should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. • Those acting upon information and recommendations contained within this report without contacting one of our investment advisers do so entirely at their own risk. • While this document is based on information from sources which are considered reliable, Baker Young Limited has not verified independently the information contained in the document and Baker Young Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Baker Young Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded, Baker Young Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person. **Disclosure of interest:** Baker Young Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document. **Analyst certification:** Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner. • Issued by Baker Young Limited ABN 92 006 690 320. Australian Financial Services Number 246735.